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Tumor progression: Defining the soil round the tumor seed
Lisa J. McCawley and Lynn M. Matrisian
The tumor microenvironment, or stroma, is known to
contribute to tumor progression. Two recent studies
have shown that the stromal protein matrix
metalloproteinase MMP-9 has a role in the early stages
of tumor growth and angiogenesis.
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Enormous advances have been made over the past
several decades in identifying the molecular determinants
of carcinogenesis. Alterations in specific oncogenes and
tumor suppressor genes have been identified and shown
to have causal roles in the initiation, maintenance and pro-
gression of tumors, in systems such as chemically induced
mouse skin tumors and human colorectal cancer [1,2].
This genome-centric view of tumor progression, however,
has largely ignored the substantial contribution of the tumor
microenvironment to the malignant phenotype [3–5].
Although the ‘seed and soil’ hypothesis of Paget [6] dates
to 1889, the molecular determinants of the ‘seed’ are
much better delineated than those of the ‘soil’ for either
primary or metastatic lesions. But two groups [7,8] have
now identified an enzyme produced by the normal cellular
component of the tumor that is a critical player in skin and
pancreatic islet carcinogenesis.
Matrix metalloproteinases are a family of over 20 enzymes
that are characterized by their ability to degrade the
extracellular matrix (ECM) and their dependence upon
Zn2+ binding for proteolytic activity [9]. These proteinases
have been implicated in a variety of normal and pathologi-
cal cellular processes, including organ involution, wound
healing and tumor cell invasion. Because of their matrix-
degrading activity, and the correlation between high levels
of their enzymatic activity and elevated tumor metastasis,
matrix metalloproteinases were initially thought to act by
destroying the basement membrane and other compo-
nents of the ECM, and thereby facilitating tumor cell
invasion and metastasis. Recent work, however, has shown
that matrix metalloproteinases make other contributions
to tumor progression, for example by effects on cell prolif-
eration, survival and angiogenesis [10].
At the same time as we have begun to understand the
multiple roles played by matrix metalloproteinases in
tumor progression, a broadening picture has developed of
the functions of both the ECM and the non-matrix sub-
strates of matrix metalloproteinases. The latter substrates
include other matrix metalloproteinases, which are acti-
vated by proteolysis, as well as cell-surface and matrix-
bound growth factors, which are released by proteolysis
[11]. Thus, today matrix metalloproteinases are known to
function at multiple steps of tumor progression through
mechanisms that include the proteoylsis of both matrix
and non-matrix targets.
Matrix metalloproteinases have been considered promis-
ing targets for anti-cancer drugs, and a number of synthetic
matrix metalloproteinase inhibitors have been developed
and tested [12,13]. Because of the unexpected side effects
of such inhibitors — joint pain and immobility — it has
become of critical importance to identify the specific
matrix metalloproteinases involved in tumor progression.
Progress towards this end has recently been reported by
two groups [7,8] who have effectively combined use of
well-characterized mouse models of tumorigenesis with
targeted ablation of individual matrix metalloproteinases.
The two groups both used mice with targeted mutations
of the MMP-9 gene, but they used distinct tumor models:
skin tumorigenesis in one case [7], and pancreatic islet
cancer in the other [8]. 
MMP-9, otherwise known as gelatinase B or 92 kDa type
IV collagenase, is characterized by its ability to cleave
basement membrane and denatured collagens (gelatin)
[9]. MMP-9 is produced by a variety of cell types, includ-
ing epithelial cells, fibroblasts, endothelial cells and inflam-
matory cells. Targeted ablation of MMP-9 is not lethal in
mice, but it does cause a mild skeletal defect. The skeletal
growth plate of the mutant mice showed a delayed devel-
opment, characterized by a delay in apoptosis, vasculariza-
tion and ossification in the developing hypertrophic
chondrocytes [14]. The existence of viable, healthy MMP-
9 null mice allowed investigation into the specific contri-
bution of MMP-9 to tumor progression.
Coussens et al. [7] examined the effects of MMP-9
ablation in a transgenic skin model of tumorigenesis, in
which the early gene regions of the human papilloma type
16 (HPV16) genome are expressed under the control of
the keratin 14 promoter. These mice develop hyperplasias
in the squamous epithelium on their trunk and ears, which
progress into squamous cell carcinomas with a 50% inci-
dence by one year of age. In earlier work, the group [15]
demonstrated that tumor progression in this mouse model
is accompanied by angiogenesis coupled with an influx of
mast cells and enhanced levels of active MMP-9. Now
Coussens et al. [7] have gone on to determine the contri-
bution of MMP-9 to skin tumorigenesis directly, by cross-
ing the MMP-9 null mice with the K14-HPV16 mice.
The progeny of this cross that are both null for MMP-9
and carry the K14-HPV16 transgene were found, at one
year of age, to have a reduced incidence of squamous cell
carcinoma and reduced cell proliferation, compared to
wild-type, K14-HPV16 transgenic counterparts. Inflamma-
tory cells — particularly mast cells, neutrophils, and
macrophages — were the primary sites of MMP-9
production. Using a strategy previously shown to reverse
the effects of MMP-9 ablation on skeleton [14], bone
marrow cells from wild-type mice were introduced into
the MMP-9 null, K14-HPV16 transgenic animals [7]. The
response was striking. All of the wild-type phenotypes
were restored, including the proliferative response and the
incidence of squamous cell carcinoma at one year of age
[7]. This suggests that MMP-9-expressing bone marrow
cells are involved in regulating cell proliferation and tumor
progression in the K14-HPV16 model of skin tumorigenesis.
Bergers et al. [8] took a similar approach to investigating
the role of MMP-9 in pancreatic islet carcinoma. They
used a transgenic model of pancreatic cancer, RIP1-Tag2
mice whose insulin-producing beta cells express SV40 T
antigen. The islets of these transgenic mice undergo a
well-defined progression from hyperplastic, precancerous
nodules to large invasive carcinomas over a 14 week time
period. An angiogenic response is a critical step in the pro-
gression of these tumors. An earlier study [16] investigated
the effects of the synthetic, broad-spectrum matrix metal-
loproteinase inhibitor BB-94 on tumor progression in this
model system. BB-94 was found to reduce angiogenesis in
precancerous islets and also growth of tumors when given
at an early stage in progression.
In their more recent study, Bergers et al. [8] addressed
the roles of MMP-9 and MMP-2, another gelatinase, in
pancreatic islet carcinoma by crossing MMP-9 or MMP-2-
deficient animals with RIP1-Tag2 mice [8]. The MMP-9-
deficient, RIP1-Tag2 transgenic progeny showed reduced
angiogenesis and tumor growth; but while the MMP-2-
deficient, RIP1-Tag2 transgenic progeny also showed
reduced tumor growth, they developed similar angiogenic
lesions in the hyperproliferative islet cells to wild-type con-
trols. The distinction between the angiogenic response of
pancreatic islets in the presence of MMP-9 or MMP-2 was
also apparent in vitro: treatment of normal islets with
MMP-9, but not MMP-2, could generate a morphogenic
response in endothelial cells. Interestingly, MMP-9 expres-
sion was localized, not to the transgene-expressing epithe-
lial cells, but to a small number of cells in close apposition
to the vasculature characteristic of infiltrating inflammatory
cells. These results indicate that stromal MMP-9 plays an
important role in establishing the tumor vasculature.
The substrate responsible for MMP-9’s activity in
angiogeneis has not been clearly established, but has been
suggested to be vascular endothelial growth factor
(VEGF) which is released from vascular basement mem-
brane and the ECM in the RIP1-Tag2 model. Bergers et al.
[8] showed that VEGF is critical for the angiogenic switch,
but that the growth factor and its receptors are expressed
constitutively in RIP1-Tag2 mice. They found that MMP-9
null mice show reduced coupling of VEGF with one of its
receptors in the angiogenic pre-cancerous islets, and
in vitro studies indicated that the release of VEGF into the
supernatant is influenced by MMP-9 [8]. The role of
MMP-9 in this system thus appears to be to facilitate the
accessibility of angiogenic molecules to endothelial cells,
an activity that represents ‘seed and soil’ interactions.
One insight from these studies [7,8] that is of particular
interest is the early stage of tumor progression at which
matrix metalloproteinase ablation was effective. In con-
trast to the notion that matrix metalloproteinases facilitate
tumor invasion and metastasis, the new studies [7,8] support
the view that MMP-9 plays a role in the control of cell pro-
liferation and the angiogenic switch, and is a determinant
of the overall tumor burden. In fact, in the K14-HPV16
skin tumorigenesis model, although fewer tumors devel-
oped in the absence of MMP-9, a higher proportion of
those that did develop had a phenotype characteristic of
more highly malignant cancers [7]. Furthermore, adminis-
tration of the matrix metalloproteinase inhibitor BB-94 at
both early and intermediate stages of tumor progression
in the RIP1-Tag2 model reduced the tumor burden, but
had no effect on large, established tumors [16]. Thus, the
absence of MMP-9 retarded tumor development in early
stages of establishment and growth, but did not impede
the progression of well established tumors to a more
advanced stage.
These results have important implications for the use of
matrix metalloproteinase inhibitors in a clinical setting.
Several matrix metalloproteinase inhibitors have reached
the stage of clinical trials as anti-angiogenic or anti-
metastatic agents, and have been tested for their efficacy
in the treatment of advanced pancreatic, gastric, prostate
and lung cancer [12]. The results of the phase III trials
with matrix metalloproteinase inhibitors have been disap-
pointing, with no beneficial effects of matrix metallopro-
teinase inhibition; indeed, in one study, patients treated
with a matrix metalloproteinase inhibitor performed worse
than placebo-treated controls [13,17]. An exception to this
gloomy scenario is gastric cancer, where treatment with
the matrix metalloproteinase inhibitor marimastat was
found to have a beneficial effect on the survival of patients
with no evidence of metastatic disease [18].
The clinical data are therefore consistent with the results
reported by Coussens et al. [7] and Bergers et al. [8,16]:
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matrix metalloproteinase inhibition has little impact on
advanced-stage tumors, but it can be effective if the
inhibitor is administered during earlier stages of tumor
progression. Matrix metalloproteinase inhibition has also
been shown to be effective in the early stages of intestinal
tumor formation. In a mouse model of intestinal tumor
progression, animals that were either deficient in MMP-7
(also known as matrilysin) or treated with a synthetic
matrix metalloproteinase inhibitor were found to develop
a reduced number of benign tumors [19,20]. Matrix
metalloproteinase inhibition could thus be considered as a
strategy for preventing the progression of tumors from a
premalignant to a malignant state.
Why does MMP-9 activity appear to be more critical in
early stages of tumor progression? This may mean that
matrix metalloproteinase activity is essential early on,
when the tumor is being established and harnessing criti-
cal functions of the surrounding stroma, but does not play
an indispensable role in maintenance of the tumor. A
number of genetic and epigenetic changes occur through-
out tumorigenesis [1–5]. As the tumor progresses, there
are more signals serving redundant functions and any one
of these becomes less critical for maintaining overall
tumor survival (Figure 1). The recent studies [7,8] suggest
that MMP-9 has a critical role in early stages of pancreatic
islet and skin tumorigenesis; loss of just one matrix
metalloproteinase, however, does not eliminate tumor
formation altogether. The results support the view that
matrix metalloproteinase inhibitors would be more effica-
cious in cancer treatment if given at an earlier stage, and in
combination with other therapies.
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Figure 1
Tumor–stroma communication during tumor progression. The diagram
illustrates tumor progression from a hyperplastic, premalignant stage
through the ‘angiogenic switch’ to an invasive, metastatic cancer. The
colored arrows indicate lines of communication between tumor cells
and surrounding stromal components of the tumor, including
fibroblasts, endothelial cells, inflammatory cells and structural matrix
components. The gold arrows may be representative of the
contribution of matrix metalloproteinases, which represent a greater
proportion of the communication signals in early, as compared to later
stages of tumor progression.
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